Citigroup’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History
Bought
Maintained
Sold
Other funds holding MLNT
GIM
CCM
OAM
ARTA
Citigroup's MLNT Position: Q4 2019 in Review
Citigroup sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 783 shares — an estimated $3K sold.
Citigroup first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $46K in Q3 2018. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.
- Citigroup reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Citigroup sold 783 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $3K.
- Citigroup first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
- Citigroup's Melinta Therapeutics, Inc. Common Stock position peaked at $46K in Q3 2018.
- 37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.